As in the targeted monotherapies, also in the combinatorial setting, routine multi-gene NGS of both tissue and circulating tumor DNA is now the standard of care, with the 2025 NCCN guideline mandating HRR-gene screening (BRCA1/2, ATM, PALB2, etc.)for every mCRPC patient [65]. Here, PALB2 is linked to neoplasm.